Healthcare News

Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and...

EssilorLuxottica announces S&P Global’s rating upgrade to A+ Paris, France (October 23, 2026) – EssilorLuxottica announces today that S&P Global Ratings has upgraded the Group’s long-term...

EssilorLuxottica annonce le relèvement à A+ de sa note S&P Global Ratings Paris, France (23 octobre 2026) – EssilorLuxottica annonce aujourd'hui que la note de crédit à long terme S&P Global...

EssilorLuxottica annuncia l’upgrade del rating ad A+ da parte di S&P Global Parigi, Francia (23 ottobre 2026) – EssilorLuxottica annuncia che S&P Global Ratings ha aggiornato il rating...

FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for...

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70%...

Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED...

RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced the wait for the first available echocardiography appointment at its...

Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer

EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients...